Influence Of CD133+ Expression On Patients Survival And Resistance Of CD133+ Cells To Antitumor Agents In Gastric Cancer | 3372
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Influence of CD133
expression on patients? survival and resistance of CD133
cells to anti-tumor agents were studied in
gastric cancer (GC).
Methods & Results:
As revealed by Western blot, the lower CD133
group had a significantly better survival as compared to the higher
group (P=0.014). From CD133
subpopulation (28.0% ? 2.0%) for KATO-III cells, the highest content ratio among four
measured cells lines and cancerous ascites from GC patient, could be enriched following the immunomagnetic separation (IMS) (91.0%
? 3.0%) and then at 1 wk of floating culture (95.0% ? 2.0%). The population doubling time was 21.0 ? 3.0 h vs. 40.0 ? 8.0 h in CD133
cells by CCK-8 assay; respectively (P<0.05). As shown, a single CD133
cell was capable of generating new cell colony and
the tumorigenicity rate in nude mice was 100.0% (5/5) for CD133
clonal spheres or for CD133
cells, but 0.0% (0/5) for CD133
The significantly higher mRNA level of Oct-4, Sox-2, Musashi-1, and ABCG2 in CD133
clonal spheres could be identified comparing
to that in either CD133
cells or in CD133
cells. Under the treatment of 5-FU, cisplatin or VP-16, CD133
cells had significantly lower
suppression rates of cell growth in comparison with those in CD133
cells while lower level of Bcl-2 mRNA and higher level of Bax
mRNA were simultaneously found in CD133
cells comparing to that in CD133
The patients with lower CD133
expression had a better survival. Enriched CD133
cells in clonal sphere with higher
mRNA level of Oct-4, Sox-2, Musashi-1, and ABCG2 shared the ability to be self-renewable, proliferative, tumorigenic and resistant to
anti-tumor agent as probably regulated by genetic products of Bcl-2 and Bax.
Ji-wei Yu has completed her M.D. at the age of 25 years from Shanghai Jiao-tong University School of Medicine and postdoctoral studies for Ph.D.
from Shanghai Jiao-tong University School of Medicine. She is the Director of 1
Department of General Surgery. She has published more than 50
papers in reputed journals and is serving as an editorial board member of repute.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals